

Reference:	FOI.21613.26
Subject:	Biologics in Secondary Care
Date of Request:	16 September 2026

Requested:

- How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2026 and end of August 2026?
 - Benralizumab (Fasenra)
 - Depemokimab (Exdensur)
 - Dupilumab (Dupixent)
 - Lebrikizumab (Ebglyss)
 - Mepolizumab (Nucala)
 - Omalizumab (Xolair)
 - Reslizumab (Cinqaero)
 - Tezepelumab (Tezspire)
- How many patients were treated for severe asthma, COPD, CRSwNP with the following medicines in the 3 months between the start of June 2026 and end of August 2026? Please provide three columns: Severe asthma (please include all types or references to asthma) / Chronic Obstructive Pulmonary Disease (COPD) / Chronic rhinosinusitis with nasal polyps (CRSwNP).
 - Benralizumab (Fasenra)
 - Depemokimab (Exdensur)
 - Dupilumab (Dupixent)
 - Mepolizumab (Nucala)
 - Omalizumab (Xolair)
 - Reslizumab (Cinqaero)
 - Tezepelumab (Tezspire)
- How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of June 2026 and end of August 2026?
 - Dupilumab (Dupixent)
 - Lebrikizumab (Ebglyss)
- How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2026 and end of August 2026? Please provide three columns: Respiratory departments / Dermatology departments / Other departments.
 - Benralizumab (Fasenra)
 - Depemokimab (Exdensur)
 - Dupilumab (Dupixent)
 - Lebrikizumab (Ebglyss)
 - Mepolizumab (Nucala)
 - Omalizumab (Xolair)
 - Reslizumab (Cinqaero)
 - Tezepelumab (Tezspire)

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients for some of the medications due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients treated with the listed medications, for any condition, during the period 1 June to 31 August 2026.

Medication	Number
Benralizumab (Fasenra)	101
Depemokimab (Exdensur)	0
Dupilumab (Dupixent)	184
Lebrikizumab (Ebglyss)	*
Mepolizumab (Nucala)	23
Omalizumab (Xolair)	*
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	184

2. The UHB provides within the table overleaf, the number of patients treated for the named conditions with the medications listed, during the period 1 June to 31 August 2026.

Name of medicine	Severe Asthma	Chronic Obstructive Pulmonary Disease (COPD)	Chronic Rhinosinusitis with Nasal Polyps (CRwNP)
Benralizumab (Fasenra)	100	0	0
Depemokimab (Exdensur)	0	0	0
Dupilumab (Dupixent)	17	0	*
Mepolizumab (Nucala)	23	0	0
Omalizumab (Xolair)	0	0	0
Reslizumab (Cinqaero)	0	0	0
Tezepelumab (Tezspire)	184	0	0

3. The UHB provides within the table below, the number of patients treated for Atopic Dermatitis (AD) with the listed medications, during the period 1 June to 31 August 2026.

Medication	Number
Dupilumab (Dupixent)	165
Lebrikizumab (Ebglyss)	*

4. The UHB provides within the table below, the number of patients treated by the Respiratory, Dermatology and other departments, with the listed medications, during the period 1 June to 31 August 2026.

Name of medicine	Respiratory departments	Dermatology departments	Other departments
Benralizumab (Fasenra)	0	91	15
Depemokimab (Exdensur)	0	0	0
Dupilumab (Dupixent)	169	15	0
Lebrikizumab (Ebglyss)	*	0	0
Mepolizumab (Nucala)	0	20	*
Omalizumab (Xolair)	0	0	*
Reslizumab (Cinqaero)	0	0	0
Tezepelumab (Tezspire)	0	166	30